Global Disseminated Intravascular Coagulation Dic Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 416.96 Million |
 Market Size (Forecast Year) |
USD 532.31 Million |
 CAGR |
% |
| Major Markets Players |
>全球弥漫性血管内凝血 (DIC) 市场，按症状（出血、血栓、瘀伤、血压下降、呼吸急促、意识模糊、发烧）、治疗（药物、输血、手术等）、诊断（全血细胞计数和血涂片检查、部分凝血活酶时间 (PTT)、凝血酶原时间 (PT)、纤维蛋白原血液测试、D-二聚体等）、给药途径（口服、肠外、其他）、最终用户（医院、专科诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房、其他）– 行业趋势和预测到 2029 年。
市场分析和规模
近年来，由于癌症发病率不断上升，预计弥漫性血管内凝血 (DIC) 市场将在预测期内快速增长。根据国际癌症研究机构 (IARC) 的数据，到 2040 年，全球癌症负担预计将增加到 2750 万新病例，死亡人数将达到 1630 万。癌症是弥漫性血管内凝血 (DIC) 的主要风险因素之一。弥漫性血管内凝血 (DIC) 是一种危险的疾病，凝血蛋白会变得过度活跃。
Data Bridge Market Research 分析称，2021 年弥漫性血管内凝血 (DIC) 市场价值为 4.16961 亿美元，预计到 2029 年将达到 5.3231 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 3.10%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
市场定义
弥漫性血管内凝血 (DIC) 是一种罕见疾病，会导致血流问题。这是一种凝血问题，会导致无法控制的出血。大约 10% 的败血症患者、癌症或胰腺炎等疾病患者以及从烧伤或妊娠和分娩期间严重问题等创伤中恢复的患者都患有 DIC。
报告范围和市场细分
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制至 2019 - 2014） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
症状（出血、血栓、瘀伤、血压下降、呼吸短促、意识模糊、发烧）、治疗（药物、输血、手术等）、诊断（全血细胞计数和血涂片检查、部分凝血活酶时间 (PTT)、凝血酶原时间 (PT)、纤维蛋白原血液测试、D-二聚体等）、给药途径（口服、肠胃外、其他）、最终用户（医院、专科诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房、其他） |
|
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Hikma Pharmaceuticals PLC (UK), Fresenius Kabi AG (Germany), Eisai Co., Ltd. (Japan) |
|
Market Opportunities |
|
Disseminated intravascular coagulation (DIC) market Dynamics
Drivers
- Increasing prevalence of cancer
The rising prevalence of cancer is a primary driver of the disseminated intravascular coagulation (DIC) market's growth. Along with this, blood transfusion reaction, pregnancy complications, inflammation of the pancreas, liver disease, and infection in the blood are the risk factors of DIC that will further influence the market dynamics during the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of disseminated intravascular coagulation (DIC) market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the disseminated intravascular coagulation (DIC) market. Additionally, high disposable income and increasing incidences of severe tissue injury such as burns and head injury will result in the expansion of disseminated intravascular coagulation (DIC) market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the disseminated intravascular coagulation (DIC) market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the disseminated intravascular coagulation (DIC) market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment of disseminated intravascular coagulation (DIC) will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the disseminated intravascular coagulation (DIC) market. Additionally, complications involved with disseminated intravascular coagulation (DIC) such as lack of blood flow to arms, legs, bleeding, stroke and others will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This disseminated intravascular coagulation (DIC) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the disseminated intravascular coagulation (DIC) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Disseminated intravascular coagulation (DIC) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Disseminated intravascular coagulation (DIC) market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of disseminated intravascular coagulation (DIC) in recent months.
Global disseminated intravascular coagulation (DIC) market Scope
The disseminated intravascular coagulation (DIC) market is segmented on the basis of symptoms, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Symptoms
- Bleeding
- Blood Clots
- Bruising
- Drop in Blood Pressure
- Shortness of Breath
- Confusion
- Fever
On the basis of symptoms, the disseminated intravascular coagulation (DIC) market is segmented into bleeding, blood clots, bruising, drop in blood pressure, shortness of breath, confusion, and fever.
Treatment
- Medicines
- Transfusions
- Surgery
- Others
Based on treatment, the disseminated intravascular coagulation (DIC) market is segmented into medicines, transfusions, surgery and others. The medication section is further categorized into antibiotics, heparin and antithrombin which may be used to help with coagulation problems.
Diagnosis
- Complete Blood Count with Blood Smear Exam
- Partial Thromboplastin Time (PTT)
- Prothrombin Time (PT)
- Fibrinogen Blood Test
- D-dimer
- Others
On the basis of diagnosis, the global disseminated intravascular coagulation (DIC) market is segmented into complete blood count with blood smear exam, partial thromboplastin time (PTT), prothrombin time (PT), fibrinogen blood test, D-dimer and others.
Route of Administration
- Oral
- Parenteral
- Others
The route of administration segment for the disseminated intravascular coagulation (DIC) market is segmented into oral, parenteral and others.
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end-users, the disseminated intravascular coagulation (DIC) market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the disseminated intravascular coagulation (DIC) market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
Disseminated intravascular coagulation (DIC) market Regional Analysis/Insights
The Disseminated intravascular coagulation (DIC) market is analysed and market size insights and trends are provided by country, symptoms, treatment, drug class, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Disseminated intravascular coagulation (DIC) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the disseminated intravascular coagulation (DIC) market because of the rising healthcare expenditure and adoption of advanced technologies in this region. Additionally, growing demand for advanced treatment options for this disease will further propel the market’s growth rate in this region.
Europe is expected to grow during the forecast period of 2022 to 2029 due to growing prevalence of disseminated intravascular coagulation (DIC) and growing focus of major key players on novel technology in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Disseminated Intravascular Coagulation (DIC) Market Share Analysis
The Disseminated intravascular coagulation (DIC) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to disseminated intravascular coagulation (DIC) market.
Some of the major players operating in the disseminated intravascular coagulation (DIC) market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.（耶路撒冷）
- 赛诺菲（法国）
- 辉瑞公司（美国）
- 葛兰素史克公司 (英国)
- 诺华公司（瑞士）
- 拜耳公司（德国）
- 礼来公司 (美国)
- 默克公司（美国）
- 艾尔建（爱尔兰）
- 阿斯利康（英国）
- AbbVie Inc.（美国）
- 强生私人有限公司（美国）
- Cipla Inc.（美国）
- 雅培（美国）
- 默克集团（德国）
- Hikma Pharmaceuticals PLC（英国）
- 费森尤斯卡比公司（德国）
- 卫材株式会社（日本）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
